ライフサイエンスコーパス: lean body mass

1 hip ratio to 1.37 [95% CI: 1.33 to 1.42] for lean body mass).

2 ose homeostasis, decreased fat and increased lean body mass.

3 ed rate of fatty acid, beta-oxidation, and a lean body mass.

4 difference in both skeletal muscle mass and lean body mass.

5 no significant difference in percent fat and lean body mass.

6 ic cancer patients for effects on weight and lean body mass.

7 ntake, increased metabolic rate, and loss of lean body mass.

8 f negative energy balance but does not alter lean body mass.

9 strength and physical skills, and increased lean body mass.

10 sult in low serum protein levels and loss of lean body mass.

11 c response, with protein wasting and loss of lean body mass.

12 ugh BMI does not distinguish between fat and lean body mass.

13 lts in increased fat mass without changes in lean body mass.

14 II) subjects is in excess of the increase in lean body mass.

15 ite and an increase in metabolism of fat and lean body mass.

16 dieting because the latter reduces maternal lean body mass.

17 se experience weight loss, including loss of lean body mass.

18 biquitin-proteasome pathway leads to reduced lean body mass.

19 rences in liver volume and/or differences in lean body mass.

20 s when these measurements were corrected for lean body mass.

21 even of eight women gained body fat and lost lean body mass.

22 anthropometric measures after adjustment for lean body mass.

23 d with negative nitrogen balance and loss of lean body mass.

24 ciated with significant increases in BMC and lean body mass.

25 d triglycerides, and decreased proportion of lean body mass.

26 secondary to an effect on fat as opposed to lean body mass.

27 ar VCAN, ADAMTSL3, and IRS1 for appendicular lean body mass.

28 lin-like growth factor-1, and enhancement of lean body mass.

29 position by reducing fat mass and increasing lean body mass.

30 6), as measured at our institution and using lean body mass.

31 nsufficient in protein could lead to loss of lean body mass.

32 t-free mass (-0.6 kg and 2.0 kg; P = 0.036), lean body mass (0.0 kg and 1.9 kg; P = 0.041), and muscl

33 weight (0.8 +/- 2.4 and 0.7 +/- 2.4 kg) and lean body mass (0.3 +/- 1.4 and 0.3 +/- 1.5 kg) did not

34 .1 +/- 0.3 v +2.3 +/- 0.7 kg; P =.002/0.04); lean body mass (+0.8 +/- 0.2 v -0.4 +/- 0.3 kg; P =.02/0

35 0.28 +/- 0.02 to 0.20 +/- 0.02 mmol FFA x kg lean body mass(-1) x h(-1); P < 0.002), as did the rate

36 overall lean body mass increased (change in lean body mass, 2.1 kg [CI, 1.3 to 2.9]) (P < 0.001), an

37 n body mass, 25 g glucose, 1 mmol glycine/kg lean body mass + 25 g glucose, or water only, given in r

38 iod after the ingestion of 1 mmol glycine/kg lean body mass, 25 g glucose, 1 mmol glycine/kg lean bod

39 ease +/- SD, 1.6 +/- 3.7 kg [P < 0.001]) and lean body mass (3.0 +/- 3.0 kg [P < 0.001]), accompanied

40 8 [13.6] vs 57.3 [7.2] g; p=0.0152) and less lean body mass (450.1 [9.6] vs 491.9 [11.7] g; p=0.0120)

41 the testosterone analog oxandrolone improves lean body mass accretion and bone mineral content and th

42 ntral fat, prevented bone loss, and improved lean body mass accretion.

43 ed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance

44 r if the processes that adapt kidney mass to lean body mass also mediate renal hypertrophy following

45 trophy subjects after routine adjustment for lean body mass and after adjustment for each organ-tissu

46 both patients with CF and control subjects, lean body mass and arm muscle area significantly correla

47 (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat).

48 ng myostatin, can prevent or restore loss of lean body mass and body weight in simian immunodeficienc

49 Lean body mass and bone mineral content did not change.

50 Lean body mass and bone mineral density at the hip decre

51 h factor therapy had significantly increased lean body mass and decreased fat mass by 6 weeks, but th

52 The significant (P<.05) increases in lean body mass and decreases in fat mass were also not d

53 oxidation was significantly correlated with lean body mass and diet.

54 et-supplemented uremic mice, which lost both lean body mass and fat mass and had an increase in basal

55 Their lean body mass and fat mass were 39.4 +/- 2.7 kg and 16.

56 oducing national reference distributions for lean body mass and fat mass, however, is currently limit

57 , elderly and young participants matched for lean body mass and fat mass.

58 nome-wide association studies for whole body lean body mass and find five novel genetic loci to be si

59 B11, VCAN, ADAMTSL3, IRS1, and FTO for total lean body mass and for three single-nucleotide polymorph

60 n of healthy body weight and preservation of lean body mass and functional ability with age.

61 eight gain or loss women were likely to lose lean body mass and gain fat mass during treatment for br

62 efficacy endpoints were the median change in lean body mass and handgrip strength over 12 weeks and w

63 ologic testosterone administration increases lean body mass and improves quality of life among androg

64 an anabolic steroid that attenuates loss of lean body mass and improves wound healing in burn patien

65 ) individuals from 33 cohorts for whole body lean body mass and in 45,090 (42,360 of European ancestr

66 The peri(-/-) animals have a greater lean body mass and increased metabolic rate but they als

67 are particularly susceptible to the loss of lean body mass and its attendant increased morbidity and

68 ines was found to have beneficial effects on lean body mass and leg power in elderly men.

69 body proteolysis suggesting that the loss of lean body mass and muscle wasting in insulinopenia is re

70 tion in whom preservation and restoration of lean body mass and neuromuscular function are crucial.

71 ange since 25 years of age, body mass index, lean body mass and percent body fat, and nonspine fractu

72 ptive glomerular changes driven by increased lean body mass and potential direct nephrotoxic effects

73 al energy expenditure, reductions in fat and lean body mass and prevention from diet-induced obesity.

74 els for the purposes of increasing strength, lean body mass and sexual performance.

75 , and was a composite of stable or increased lean body mass and stability or improvement in two of th

76 ome characterized by the progressive loss of lean body mass and systemic inflammation.

77 d increased serum levels of WISP2, increased lean body mass and whole body energy expenditure, hyperp

78 finding does not appear to be a function of lean body mass and, although modified by certain patient

79 astating effects of the loss of body weight, lean body mass, and adipose tissue were recognized as co

80 Weight, lean body mass, and body surface area in the denominator

81 ection and after normalizing to body weight, lean body mass, and body surface area, and simplified me

82 Weight; body fat, lean body mass, and bone mineral content (measured by du

83 ical impedance-derived measures of fat mass, lean body mass, and fat percentage.

84 Cellular mass, lean body mass, and fat were assessed "directly" by tota

85 ratory fitness, functional task performance, lean body mass, and fatigue, with inconsistent effects o

86 9%) increased food intake, body weight gain, lean body mass, and gastrocnemius muscle mass as compare

87 elated peptide, resist tumor-induced loss of lean body mass, and maintain normal circadian activity p

88 t with growth hormone increases body weight, lean body mass, and treadmill work output and appears to

89 Low values of serum proteins and loss of lean body mass are commonly found in patients with chron

90 to the profound catabolic state and loss of lean body mass associated with the AIDS wasting syndrome

91 Oxandrolone improved lean body mass, bone mineral content and muscle strength

92 ere burn, oxandrolone significantly improves lean body mass, bone mineral content, and muscle strengt

93 Height, weight, lean body mass, bone mineral content, cardiac function,

94 improved if adjusted by body surface area or lean body mass but was improved if adjusted by height (r

95 n affected energy expenditure and storage of lean body mass, but not body fat storage.

96 Anamorelin significantly increased lean body mass, but not handgrip, strength in patients w

97 ith baseline, significant increases in total lean body mass by day 113 or end of study were noted in

98 Primary outcome was lean body mass by dual-energy x-ray absorptiometry over

99 The lean body mass (by dual-energy X-ray absorptiometry) inc

100 (TNF) and IL-1, induce anorexia and loss of lean body mass, common manifestations of acute and chron

101 enic compounds with undoubted effects on the lean body mass compartment.

102 fication of proteins which determine fat and lean body mass composition is critical to better underst

103 dations during energy deficit (ED) preserves lean body mass, concerns have been raised regarding the

104 n have greater clearance of ethanol per unit lean body mass, confirming previous oral alcohol adminis

105 Lean body mass, consisting mostly of skeletal muscle, is

106 methods including percentage change in SUVs, lean body mass-corrected (SUL) SULpeak, SULmax, and tota

107 Lean body mass correction of the SUVmax did not change a

108 ated with height, total or central body fat, lean body mass, current smoking, physical activity, or c

109 placebo, weight (increase, 0.1 +/- 3.1 kg), lean body mass (decrease, 0.1 +/- 2.0 kg), and body fat

110 s. males: -0.05+/-0.007%) and an increase in lean body mass (Delta females: 5+/-4% vs. Delta males: -

111 Lean body mass determined by DXA was highly correlated w

112 ice; however, the fat mass was decreased and lean body mass did not change.

113 yielded similar results, and adjustments for lean body mass did not substantially alter the findings.

114 Prior to and after bed rest, lean body mass (dual-energy X-ray absorptiometry) and qu

115 morphisms were significantly associated with lean body mass either genome wide (p < 5 x 10(-8)) or su

116 Juvenile lean body mass, estimated using urinary creatinine excre

117 thermore, NBI-12i-treated uremic mice gained lean body mass, fat mass, and had a lower basal metaboli

118 The primary endpoint was change in total lean body mass from baseline, assessed by dual-energy x-

119 duced a microbiota-dependent augmentation of lean body mass gain, changed bone morphology, and altere

120 ry taxa in recipient animals correlated with lean body mass gain; liver, muscle, and brain metabolism

121 At 6 weeks, lean body mass had increased and total fat mass had decr

122 Fat and lean body mass have important implications for health an

123 s were body mass index, body fat percentage, lean body mass, high-density lipoprotein cholesterol, lo

124 ation remained substantial when adjusted for lean body mass (highest HR: 1.05 [95% CI: 1.01 to 1.10]

125 accumulate relatively more body fat and less lean body mass, ie, muscle and bone.

126 ood and skeletal muscle ammonia, increase in lean body mass, improved grip strength, higher skeletal

127 week, which will promote the maintenance of lean body mass, improvements in muscular strength and en

128 ely correlated to body weight, fat mass, and lean body mass in adolescent, perimenopausal, and elderl

129 n II (AngII) could contribute to the loss of lean body mass in chronic kidney disease, but the mechan

130 dy weight, muscle mass, muscle strength, and lean body mass in HIV-infected men with weight loss and

131 rotein supplement did not increase weight or lean body mass in HIV-positive subjects who were eating

132 nds, significantly increases strength and/or lean body mass in humans by increasing testosterone leve

133 ate with inflammation and predict changes in lean body mass in patients with CKD, and activation of t

134 n greater relative increases in both fat and lean body mass in the undernourished rats when compared

135 -2.1 kg [95% CI, -2.8 to -1.35] and overall lean body mass increased (change in lean body mass, 2.1

136 (from 31.9% +/- 6.5% to 28.3% +/- 7.0%), and lean body mass increased (from 59.0 +/- 8.5 kg to 61.5 +

137 Lean body mass increased at a steeper rate in males (P<0

138 Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg

139 Over 12 weeks, lean body mass increased in 38 patients in the anamoreli

140 Lean body mass increased in growth hormone recipients co

141 Over 12 weeks, lean body mass increased in patients assigned to anamore

142 Lean body mass increased significantly in patients given

143 The adjustment of PkVO2 to lean body mass increases the prognostic value of cardiop

144 Seven lean (body mass index < 25 kg/m(2)), young, sedentary IR

145 sk associated with SHBG rs6259 was found for lean (body mass index <23) postmenopausal minor allele c

146 Ten lean (body mass index, 19-25 kg/m(2)), healthy Caucasian

147 eference curves for fat mass index (FMI) and lean body mass index (LBMI) and evaluate the effects of

148 Both men and women were remarkably lean: body mass index = 21.3 (3.6) and 23.0 (5.2) kg/m2,

149 Lean body mass is an important predictor of survival and

150 Loss of lean body mass is common in patients with acute or chron

151 l anabolic strategies to reverse the loss of lean body mass is of critical importance to increase sur

152 dence suggests that growth hormone increases lean body mass, it may not improve strength; in addition

153 (body mass index, body fat (%), weight (kg), lean body mass (kg), and fat mass (kg)) were significant

154 % +/- 0.007 nmol/100 mL leg/min) and loss of lean body mass (LBM) (-4.1% +/- 1.9%); P < 0.05.

155 s for estimation of total body fat (TBF) and lean body mass (LBM) (n = 10,525) were followed for 13.6

156 stration to elderly individuals can increase lean body mass (LBM) and decrease fat, but interactive e

157 It is not clear how lean body mass (LBM) and fat mass (FM) compare in their

158 e associations of early nutrition with adult lean body mass (LBM) and muscle strength in a birth coho

159 ) was assessed by hyperinsulinemic clamp and lean body mass (LBM) and total body fat were assessed by

160 rolled RCT was powered on a 5% difference in lean body mass (LBM) at 1 month.

161 omputerized scheme that evaluates whole-body lean body mass (LBM) based on CT data from limited-whole

162 ined the effect of body mass index (BMI) and lean body mass (LBM) depletion on handgrip (HG) force an

163 rther aim was to estimate a patient-specific lean body mass (LBM) from these MR-AC data.

164 Lean body mass (LBM) is a complex trait for human health

165 Primary outcomes included change in lean body mass (LBM) measured by dual-energy x-ray absor

166 A profound loss of lean body mass (LBM) occurred in both groups during the

167 lness of creatinine excretion as an index of lean body mass (LBM) or muscle mass in healthy men and w

168 Repletion of lean body mass (LBM) that patients lose in human immunod

169 dependent contributions of fat mass (FM) and lean body mass (LBM) to body weight, which vary accordin

170 al status on serum ferritin, after change in lean body mass (LBM) was controlled for, were evaluated

171 ne-third of that of 18 AL (P < 0.001), while lean body mass (LBM) was unchanged.

172 +/- 2, 17 +/- 2, and 22 +/- 2 pmol x kg(-1) lean body mass (LBM) x min(-1) (P < 0.05, days 5 and 10

173 ion of EE by either total body mass (TBM) or lean body mass (LBM), 2) compared the independent contri

174 ine, p < 0.01); after adjustment for age and lean body mass (LBM), DES excretion in rapid decliners w

175 ptake lean body mass (SUL), calculated using lean body mass (LBM), is essential for the semiquantific

176 e during an energy deficit helps to preserve lean body mass (LBM), particularly when combined with ex

177 Lean body mass (LBM), skeletal muscle index (SMI), and f

178 Control patients lost 8 +/- 1% of their lean body mass (LBM), whereas oxandrolone-treated patien

179 ith HIV lipodystrophy [33.2 +/- 0.27 kcal/kg lean body mass (LBM)] than for both HIV-infected and hea

180 able content of the diet with the percentage lean body mass (%LBM) or change in %LBM in older subject

181 tandardized uptake value (SUV) normalized by lean body mass ([LBM] SUL) is becoming a popular metric

182 iometry-assessed body composition (including lean body mass [LBM], appendicular lean mass [ALM], and

183 ngs provide new insight into the genetics of lean body mass.Lean body mass is a highly heritable trai

184 severity score, lower body mass index, lower lean body mass, less participation in organized sports,

185 in the tumor-bearing mice and reverse their lean body mass loss.

186 When indexed to lean body mass, LV growth in the II subjects was abolish

187 milligrams of glucose uptake per kilogram of lean body mass (M(lbm)) per minute).

188 mal glucose tolerance and 12 age-, sex-, and lean body mass-matched healthy control subjects underwen

189 Differences in bone density and trunk lean body mass may account for some of these measured di

190 In addition, greater lean body mass may be a cause.

191 Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001)

192 Fat and lean body mass measured by dual-energy x-ray absorptiome

193 The use of <19 ml O2/kg of lean body mass/min as a cutoff in PkVO2 should be used f

194 owed that a nodal standardized uptake value (lean body mass) more than 1.8 had a positive predictive

195 Secondary clinical end points were weight, lean body mass, muscle mass, exercise functional capacit

196 onstrated progressive decreases in body fat, lean body mass, muscle power, and nitrogen balance and a

197 n = 38,292) and appendicular (arms and legs) lean body mass (n = 28,330) measured using dual energy X

198 [95% CI, 165-289 kcal/d]) and body protein (lean body mass) (normal protein diet: 2.87 kg [95% CI, 2

199 The highest correlation between Ki and lean body mass-normalized SUV was found for the interval

200 Consistent with the increased lean body mass of s/s animals, locomotor activity and ac

201 To determine whether the lean body mass of well-nourished women was mobilized to

202 ssed by the change in SUVpeak, normalized to lean body mass, of the most (18)F-FDG-avid lesion (PERCI

203 h as the "constant" hydration coefficient of lean body mass or the "constant" density of fat-free mas

204 ixel value in the numerator and with weight, lean body mass, or body surface area in the denominator.

205 Water, 25 g glucose, 1 mmol lysine/kg lean body mass, or lysine plus glucose was given on sepa

206 mble chronic inflammatory disease [decreased lean body mass, osteopenia, low-grade anemia, decreased

207 n excess of maternal nitrogen in the form of lean body mass over that deposited in the fetus and the

208 ificantly increased skeletal muscle mass and lean body mass over time.

209 o eat (P = 0.356; SED: 3.7), preservation of lean body mass (P = 0.334; SED: 0.2), and loss of percen

210 ic rate (PCR), transferrin, cholesterol, and lean body mass per height.

211 5.4 [SE 4.0] vs 60.6 [7.2] micromoles per kg lean body mass per min; p=0.023) owing to a reduction in

212 -SD] change, 1.5 +/- 2.1 mg of glucose/kg of lean body mass per minute vs. -0.4 +/- 1.6 mg/kg per min

213 adjusted model (which included age, age(2), lean body mass, pulse rate, pulse pressure, hormone-repl

214 ), which was attenuated after adjustment for lean body mass (r = 0.25, P = 0.08).

215 tively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in th

216 related closely with body size, particularly lean body mass (r=.69, P<.0001) and systolic (r=.35, P<.

217 eater antecedent weight loss and a lower fat/lean body mass ratio.

218 on can be explained solely by a reduction in lean body mass remains controversial.

219 nintentional loss of body weight and loss of lean body mass (sarcopenia).

220 nt feeding and fat mass after adjustment for lean body mass, sex, birth weight, maternal obesity, rac

221 Lean body mass significantly increased in the GHRH group

222 Body weight, lean body mass, SIV titers, and somatometric measurement

223 SUV corrected for lean body mass (SUL and SULpeak) were obtained.

224 mum standardized uptake values corrected for lean body mass (SUL(max)) on (18)F-FDG PET predicted pat

225 02) [standardized uptake value corrected for lean body mass (SUL) = 5.42 +/- 2.77, 8.04 +/-3.25 and 1

226 e value calculated on the basis of predicted lean body mass (SUL) on these images, and we calculated

227 ed uptake value (SUV) corrected by predicted lean body mass (SUL) was calculated and compared.

228 Standardized uptake values corrected for lean body mass (SUL) were determined for several normal

229 The standardized uptake lean body mass (SUL), calculated using lean body mass (L

230 ke, standardized uptake value normalized for lean body mass (SUV-lean) was measured 1 h after FDG inj

231 weight (SUVbw), ideal body weight (SUVibw), lean body mass (SUVlbm), and body surface area (SUVbsa)

232 The standard uptake value normalized for lean body mass (SUVlean) in tumors was measured 50-60 mi

233 The mean values for lean body mass, Tanner stage, height-for-age Z score and

234 d patients, leading to a progressive loss of lean body mass that was not prevented by nutritional sup

235 To further keep erosion of lean body mass to a minimum, administration of anabolic

236 ain further insight into the relation of the lean body mass to REE and to better understand differenc

237 SURs calculated with weight versus lean body mass versus body surface area in the denominat

238 t of the 9 measures left the association for lean body mass virtually unchanged (lowest HR: 1.33 [95%

239 SUVmax corrected for lean body mass was 0.4-12.1 (mean +/- SD, 2.1 +/- 2.0).

240 Lean body mass was 42% greater in men than in women.

241 stic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at b

242 However, after developing HF, loss of total lean body mass was disproportionate; men with HF lost 65

243 Change in lean body mass was greater in those treated with growth

244 Lean body mass was maintained in women who exclusively b

245 2) Erosion of lean body mass was not attenuated by increased caloric b

246 Lean body mass was preserved throughout lactation in wel

247 y) subjects from 25 cohorts for appendicular lean body mass was successful for five single-nucleotide

248 Lean body mass was the predominant anthropometric risk f

249 Chronic MFP dosing for 25 days increased lean body mass, weight gain, and bone mineral density si

250 nation rate and liver volume per kilogram of lean body mass were 33% and 38% higher in women than in

251 vity levels, energy expenditure (Vo(2)), and lean body mass were all better sustained with age in rat

252 Standardized uptake values using lean body mass were determined over areas of interest.

253 fferent between groups at year 2; weight and lean body mass were greater at years 4 and 6, and fat ma

254 By year 4, weight, BMI, and lean body mass were greater in the high-risk than in the

255 lute measures (total fat, abdominal fat, and lean body mass) were secondary outcomes.

256 eostatic responses allowing them to maintain lean body mass when dietary protein intake is restricted

257 compensatory mechanisms designed to conserve lean body mass when dietary protein intake is restricted

258 explanation for death after the depletion of lean body mass when some body fat is still available to

259 scle protein net balance and preservation of lean body mass, which are associated with shortened hosp

260 30 patients were assessable for change in lean body mass, which increased by a mean of 1.02 kg (SD

261 rexia, negative nitrogen balance and loss of lean body mass will ensue.

262 tion, the association between higher BMI and lean body mass with natriuretic peptides may be mediated

263 Change in total lean body mass within the placebo group (median 0.02 kg,

264 e of enobosarm might lead to improvements in lean body mass, without the toxic effects associated wit

265 stment of peak oxygen consumption (PkVO2) to lean body mass would yield a more accurate discriminator